114 related articles for article (PubMed ID: 9787327)
1. Familial neuroblastoma: report of a kindred with later age at diagnosis.
Lemire EG; Chodirker BN; Williams GJ; Seargeant LE; Israels SJ; Phillips SM; de Nanassy JA; Maris JM; Yanofsky RA
J Pediatr Hematol Oncol; 1998; 20(5):489-93. PubMed ID: 9787327
[TBL] [Abstract][Full Text] [Related]
2. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
3. [N-myc gene copies in children with neuroblastoma and its clinical significance].
Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
[TBL] [Abstract][Full Text] [Related]
4. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
5. Features and outcome of neuroblastoma detected before birth.
Granata C; Fagnani AM; Gambini C; Boglino C; Bagnulo S; Cecchetto G; Federici S; Inserra A; Michelazzi A; Riccipetitoni G; Rizzo A; Tamaro P; Jasonni V; De Bernardi B
J Pediatr Surg; 2000 Jan; 35(1):88-91. PubMed ID: 10646781
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
[TBL] [Abstract][Full Text] [Related]
7. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
8. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
[TBL] [Abstract][Full Text] [Related]
9. Management and outcome of stage 3 neuroblastoma.
Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
Matthay KK; Perez C; Seeger RC; Brodeur GM; Shimada H; Atkinson JB; Black CT; Gerbing R; Haase GM; Stram DO; Swift P; Lukens JN
J Clin Oncol; 1998 Apr; 16(4):1256-64. PubMed ID: 9552023
[TBL] [Abstract][Full Text] [Related]
11. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
12. An infant with neuroblastoma and MYCN amplification found through mass screening.
Taga T; Okamoto N; Hisano T; Tanaka T; Shimada M; Okabe H; Shimada H; Ohta S
J Pediatr Hematol Oncol; 1998; 20(5):486-8. PubMed ID: 9787326
[TBL] [Abstract][Full Text] [Related]
13. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
Rubie H; Plantaz D; Coze C; Michon J; Frappaz D; Baranzelli MC; Chastagner P; Peyroulet MC; Hartmann O;
Med Pediatr Oncol; 2001 Jan; 36(1):247-50. PubMed ID: 11464897
[TBL] [Abstract][Full Text] [Related]
14. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
15. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
Zhong ZY; Shi BJ; Zhou H; Wang WB
J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
17. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group.
Imaizumi M; Watanabe A; Kikuta A; Takano T; Ito E; Shimizu T; Tsuchiya S; Iinuma K; Konno T; Ohi R; Hayashi Y;
Tohoku J Exp Med; 2001 Oct; 195(2):73-83. PubMed ID: 11846211
[TBL] [Abstract][Full Text] [Related]
18. 10 years' neuroblastoma screening in Europe: preliminary results of a clinical and biological review from the Study Group for Evaluation of Neuroblastoma Screening in Europe (SENSE).
Erttmann R; Tafese T; Berthold F; Kerbl R; Mann J; Parker L; Schilling F; Ambros P; Christiansen H; Favrot M; Kabisch H; Hero B; Philip T
Eur J Cancer; 1998 Aug; 34(9):1391-7. PubMed ID: 9849422
[TBL] [Abstract][Full Text] [Related]
19. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.
Katzenstein HM; Bowman LC; Brodeur GM; Thorner PS; Joshi VV; Smith EI; Look AT; Rowe ST; Nash MB; Holbrook T; Alvarado C; Rao PV; Castleberry RP; Cohn SL
J Clin Oncol; 1998 Jun; 16(6):2007-17. PubMed ID: 9626197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
